Literature DB >> 1972950

Determination and importance of varicella immune status of nursing staff in a children's hospital.

M J Ferson1, S M Bell, P W Robertson.   

Abstract

A survey of nurses at the Prince of Wales Children's Hospital was conducted to determine the prevalence of immunity to varicella-zoster virus (VZ) as defined by enzyme immunoassay (EIA), and to establish the value of history as a predictor of immunity. Of the 209 nurses surveyed, 51% could recall suffering VZ infection, and with a single exception, all of this group were immune. However, despite a 95% prevalence of immunity among all nurses, 46% of those found to be immune by EIA could not recollect having VZ infection. In the event of a hospital VZ outbreak, the latter group, without serological testing, would thus need to be regarded as susceptible, and this would create a major logistical problem in staffing the affected areas. We suggest, to minimize this cause of disruption to services, that all paediatric staff with patient contact should be asked at the time of recruitment if they recall suffering VZ infection. Those who give a positive response may be considered immune, but all other staff should have their immune status assessed by EIA at the earliest opportunity.

Entities:  

Mesh:

Year:  1990        PMID: 1972950     DOI: 10.1016/0195-6701(90)90091-2

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  3 in total

1.  Occupational risk of infection by varicella zoster virus in Belgian healthcare workers: a seroprevalence study.

Authors:  G Vandersmissen; G Moens; R Vranckx; A de Schryver; P Jacques
Journal:  Occup Environ Med       Date:  2000-09       Impact factor: 4.402

2.  Varicella vaccine in pregnancy.

Authors:  D S Seidman; D K Stevenson; A M Arvin
Journal:  BMJ       Date:  1996-09-21

Review 3.  Economic evaluations of varicella vaccination programmes: a review of the literature.

Authors:  Nancy Thiry; Philippe Beutels; Pierre Van Damme; Eddy Van Doorslaer
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.